INTRODUCTION

The simultaneous presence of a pancreatic branch-duct intraductal papillary mucinous neoplasm (BD-IPMN) with radiological worrisome features and a pancreatic intraepithelial neoplasia (PanIN) in the context of a chronic IgG4 autoimmune pancreatitis (AIP) is very rare. Here, we report the case of an 81-year-old man with symptomatic BD-IPMN associated with PanIN and IgG4 AIP.

PRESENTATION OF CASE

In January 2019, an 81-year-old Caucasian man was admitted to our surgical department for acute onset of jaundice and abdominal pain. His past medical history revealed hypertension treated with beta blockers; no smoking, alcohol, or drug abuse; weight loss >15 kg in the last three months. No family history of pancreatic neoplasms was reported. At-home treatments included esomeprazole 40 mg/d and fondaparinux 2.5 mg/d. Physical examination showed normal cardiac conditions (heart rate 77 bpm, blood pressure 125/80 mm Hg, peripheral oxygen saturation 96%) and no abnormal findings in the chest or abdomen. White blood cell count was $11.4 \times 10^9$/L with 78.9% neutrophils, and C-reactive protein (CRP) was 13 mg/L. Liver function tests indicated extrahepatic biliary obstruction with
alanine aminotransferase 78 U/L, total bilirubin 8.9 mg/dL, and direct bilirubin 6.4 mg/dL. Blood levels of pancreatic amylase were high (135 U/L) and serum autoimmune antibody tests were positive (IgG4 154 mg/dL). CA 19-9 was normal (<37 U/mL), whereas CEA was >100 ng/mL (153 U/L).

Abdominal ultrasonography (US) revealed a 30-mm hypoechoic lesion in the pancreatic head anduncinate process,causing abrupt interruption and upstream dilatation of the main pancreatic duct (MPD). The lesion was further investigated by contrast-enhanced computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP). Both CT and MRI findings supported the diagnosis of pancreatic BD-IPMN in the context of a chronic pancreatitis (Figure 1): focal cystic lesion of the pancreatic head appearing hyperintense on T1-weighted and hypointense in T2-weighted MRI sequences, with multiple internal septations and upstream dilatation of the MPD (10 mm). No liver lesions were detected. CT scans also showed an interstitial pneumonia with infiltrative opacification in the periphery of lungs.

An endoscopic retrograde cholangiopancreatography (ERCP) was performed for jaundice palliation, with stenting of the common bile duct (CBD). Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was carried out to obtain a histological characterization of the pancreatic lesion: the histological examination showed nonspecific cellular atypia (of undetermined significance). Due to the symptoms and the radiological worrisome features of the pancreatic cystic lesion, the patient underwent pylorus-preserving pancreaticoduodenectomy (PPPD).

After the resection of the pancreas, the bile duct and the duodenum at 40 mm from the pylorus, restoration of gastrointestinal continuity was performed using the first jejunal loop (Child reconstruction). Firstly, we performed a termino-lateral pancreaticojejunostomy (PJ) using also a 7 Fr endo-Wirsung catheter, that was externalized through the Witzel tunneling technique. Secondly, we carried out an end-to-side hepaticojejunostomy (HJ) at least 40 mm from the PJ, using a single layer of interrupted, closely spaced, synthetic, non-absorbable sutures. Finally, we performed a termino-lateral antecolic isoperistaltic duode- nojejunostomy using interrupted, synthetic, absorbable sutures. An intraoperative histopathological examination (frozen section) of the pancreatic and CBD margins was carried out, both to assess the radicality of resection and to exclude the presence of malignancy in the resection margins: no neoplastic abnormalities were found in the examined tissue. The gallbladder was removed. Lymph nodes of the lymphatic stations 8a, 12a, 12p, 12b, 6, 4d, 8p, and 9 were taken with the specimen. Two Penrose-type surgical drains were positioned: one on the left side to protect pancreaticojejunostomy, and the other on the right side to protect hepaticojejunostomy.6,7

Nasogastric tube was removed on postoperative day (POD) 1, and clear liquids were allowed on POD 2. Blood glucose was monitored since POD 1, and amylase levels in the drainage liquids were measured on POD 1 and 5. Postoperative course was characterized by a grade A pancreatic fistula (biochemical leak, based on ISGPS 2016 criteria),8 without fever, abdominal pain, or leukocytosis. Surgical drainages were removed on POD 5, and the patient was discharged on POD 7. The follow-up visit on POD 14 confirmed the persistence of good health conditions.

2.1 | Histopathological analysis

Macroscopic and microscopic pathological examination of the pancreatic head revealed the presence of a BD-IPMN having a main diameter of 30 mm, without intramural nodules or increased wall thickness (Figure 2 A). The BD-IPMN caused upstream dilatation (≥10 mm) of the MPD. The pancreatic parenchyma displayed diffuse autoimmune inflammation (Figure 2 B,D) and multiple areas of PanIN, both of type 1 (flat epithelial lesions with tall columnar cells and basally-located nuclei with abundant supranuclear mucin) and type 2 (papillary mucinous epithelial lesions with nuclear abnormalities, loss of cellular polarity, nuclear crowding, enlarged nuclei, and hyperchromasia) (Figure 2C). Microscopic examination of autoimmune pancreatitis areas showed the characteristic plasma cell infiltrate surrounding small-sized interlobular pancreatic vessels (Figure 2D) without destruction of the ductal epithelium, associated with swirling fibrosis around ducts and veins. No neoplastic lesions were found on duodenal and periduodenal tissue; lymphovascular invasion was not present; no metastases were detected in the 20 lymph nodes examined (pT1a pN0 based on AJCC 8th Edition staging system). No neoplastic tissue was present in gastric and ileal surgical resection specimens, as well as in the gallbladder.

2.2 | Immunohistochemistry

Immunohistochemical (IHC) analysis was performed as described elsewhere.2,4 Briefly, using 4 μm formalin-fixed paraffin-embedded sections, the analysis was conducted with the standard polymer system and peroxidase methods (antigen retrieval with a heated plate and 0.01 mol/L of citrate buffer, low-pH, for 40 minutes - Dako Omnis, Denmark A/S). Immunostaining confirmed the presence of abundant IgG4-positive cells (>10 cells/HPF) in the pancreatic parenchyma (Figure 3 A), with diagnosis of IgG4-related autoimmune pancreatitis. Moreover, fascin staining revealed an invasive component of the BD-IPMN, with evident fascin-positive areas of stromal...
infiltration (DakoCytomation, clone: 55K-2, 1:100 dilution) (Figure 3B).

3 | DISCUSSION

In this report, we describe a rare case of pancreatic BD-IPMN causing jaundice and abdominal pain, which was associated with PanIN and developed on a chronic IgG4 AIP. To our knowledge, this is the first description of such an association in the literature.

AIP is a distinct form of chronic pancreatitis with an autoimmune pathogenesis, characterized by positive serum autoantibodies and increased serum levels of IgG4. The main clinical features of AIP include obstructive jaundice, recurrent abdominal pain, coexistence of extra-pancreatic...
lesions, and a remarkable response to corticosteroids. Two types of AIP have been identified: type 1 AIP (AIP1), with diffuse pancreatic fibrosis, the presence of IgG4-positive cells and a small-vessel obliterative phlebitis; and type 2 AIP (AIP2), with characteristic granulocytic epithelial lesions. AIP1 is considered to be the pancreatic manifestation of a systemic disorder called “IgG4-related disease (IgG4-RD)”, in which a variety of systemic lesions can be identified: sclerosing cholangitis (60%), retroperitoneal fibrosis (10%), interstitial pneumonitis (8%, which was present in our patient too), and tubulointerstitial nephritis (8%). Symptoms, blood test results and clinical images can simulate a pancreatic ductal adenocarcinoma (PDAC, in which IgG4 levels can be slightly elevated too), a malignant lymphoma, or other types of pancreatitis. Thus, a careful differential diagnosis is required. A targeted biopsy of the pancreas is the method of choice in cases suspected from a focal form of AIP, and in our clinic, we prefer it over other diagnostic procedures.

Pancreatic intraepithelial neoplasia (PanIN) can be associated with AIP and can be defined as a preneoplastic lesion in chronic pancreatitis. Some authors consider PanIN as a common precursor of PDAC, even if it can be described as a noninvasive epithelial microscopic neoplasm. PanIN arises from smaller pancreatic ducts and is classified as PanIN-1, PanIN-2, and PanIN-3. PanIN-1 has characteristic columnar epithelial cells and basally oriented uniform nuclei. PanIN-2 lesions are characterized by a high grade of cytoarchitectural complexity, with nuclear changes such as loss of polarity, crowding, size variability, hyperchromasia, and pseudostratification. PanIN-3 lesions show the highest grade of dysplasia: papillae and cribriform structures; enlarged, pleomorphic, and nonoriented nuclei; mitotic figures and abnormal mitoses. The prevalence of PanIN increases with age. These lesions are more common in the head of the gland (as it can be observed in PDAC), and PanIN-3 is more common in PDAC than in chronic pancreatitis. In addition, PanINs are generally more frequent in patients with chronic pancreatitis than in controls. PanIN remains a histologically well-defined precursor of PDAC; however, the frequency and speed of progression from PanINs to PDAC is an important issue that has not been defined yet. Particular attention should be paid to the presence of PanIN lesions of any grade in surgical resection margins of a PDAC, even if it doesn’t influence patient prognosis and additional surgery is not required.

Pancreatic IPMN is defined as a tumor of the pancreatic duct that produces mucin. Four histologic subtypes of this neoplasm have been described: gastric type, intestinal type, pancreatobiliary type, and oncocytic type. International guidelines distinguish three different entities based on ductal involvement: main-duct IPMN (MD-IPMN), which is aggressive and exclusively involves the MPD; branch-duct IPMN (BD-IPMN), exclusively involving the secondary ducts; and mixed IPMN (M-IPMN), involving simultaneously the MPD and the branch ducts. MD-IPMN and BD-IPMN have a low/medium malignant potential (up to 20%-25%), and BD-IPMN has often a multifocal pattern (involving multiple branch ducts). The radiological distinction between MD-, BD- and M-IPMN has prognostic relevance.

The risk of malignancy in pancreatic neoplasms that produce mucin is an important factor that should be properly stratified. Recent guidelines distinguish tumors with “worrisome features” (WF) or “high-risk stigmata” (HRS). WF includes cyst size >30 mm, thickened cyst walls, presence of mural nodules, MPD diameter of 5-9 mm, or an abrupt change in the MPD caliber. HRS includes enhanced solid component and MPD diameter >10 mm. In order to obtain a better diagnosis, as well as to avoid risk of a particularly dangerous misdiagnosis, all cysts showing WF should be evaluated by endoscopic US and eventually by a cytological examination (EUS-FNA). Anyway, if a conservative management approach is chosen, the surveillance should be strict. In case of IPMN with HRS, surgery is mandatory. All patients with cysts without WF should anyway undergo surveillance.

In conclusion, in the context of an AIP, the presence of a pancreatic lesion requires histological definition. Delaying surgery may compromise successful tumor resection, due to metastasis development or vascular involvement. In order to rule out the malignant nature of a pancreatic lesion, a percutaneous, or endoscopic biopsy is absolutely mandatory.
This case report seems to confirm the safety of recent guidelines for the surgical management of IPMN.\textsuperscript{1,4,24} In case of symptomatic BD-IPMN and/or radiological WF, considering that PanIN-3 lesions are more frequent in the presence of a PDAC, surgical intervention (ie, standard pancreatic resection only) remains mandatory.

CONFLICT OF INTEREST
The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTION
GL: contributed to the conception and design of the study, in the provision of study materials of patients, in the surgical management of patients, in the data analysis and interpretation, in the manuscript writing. LR, AG, BP and ML: contributed in medical oncology patients’ management. GC and FMW: contributed in Histopathological and Immunohistochemical analysis. ADS and VV: contributed in radiological evaluations. MS and FC: contributed in data analysis and interpretation. All authors participated in the collection and/or assembly of data. All authors read, revised and approved the final manuscript.

ORCID
Gianni Lazzarin \(\text{https://orcid.org/0000-0002-9744-6046}\)
Lucia Romano \(\text{https://orcid.org/0000-0003-0996-4490}\)

REFERENCES
1. Del Chiaro M, Verbeke C, Salvia R, et al. European experts consensus statement on cystic tumours of the pancreas. \textit{Dig Liver Dis}. 2013;45:703-711.
2. Mackay IR. Autoimmune disease. \textit{Med J Aust}. 1969;1:696-699.
3. Brat DJ, Lillemoe KD, Yeo CJ, Warfield PB, Hruban RH. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. \textit{Am J Surg Pathol}. 1998;22:163-169.
4. Tanaka M, Fernández-del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. \textit{Pancreatology}. 2017;17:738-753.
5. Manfredi R, Graziani R, Cicero C, et al. Autoimmune pancreatitis: CT patterns and their changes after steroid treatment. \textit{Radiology}. 2008;247:435-443.
6. Schietroma M, Pessia B, Carlei F, Amicucci G. Intestinal permeability changes, systemic endotoxemia, inflammatory serum markers and sepsis after Whipple's operation for carcinoma of the pancreas head. \textit{Pancreatology}. 2017;17(5):839-846.
7. Giuliani A, Lazzarin G, Romano L, et al. A case report of three synchronous tumors in the same pancreatic specimen. \textit{Ann Med Surg (Lond)}. 2019;44:79-82.
8. Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. \textit{Surgery}. 2005;138:8-13.
9. Notohara K, Burgart LJ, Yadav D, Chari S, Smyrk TC. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. \textit{Am J Surg Pathol}. 2003;27:1119-1127.
10. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD). 2011. \textit{Mod Rheumatol}. 2012;22:21-30.
11. Okazaki K, Uchida K, Matsushita M, Takaoka M. How to diagnose autoimmune pancreatitis by the revised Japanese clinical criteria. \textit{J Gastroenterol}. 2007;42(Suppl 18):32-38.
12. Ghazale A, Chari ST, Smyrk TC, et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. \textit{Am J Gastroenterol}. 2007;102:1646-1653.
13. Matsubayashi H, Takagaki S, Otsubo T, et al. Pancreatic T-cell lymphoma with high level of soluble interleukin-2 receptor. \textit{J Gastroenterol}. 2002;37:863-867.
14. Frulloni L, Scattolini C, Falconi M, et al. Autoimmune pancreatitis: differences between the focal and diffuse forms in 87 patients. \textit{Am J Gastroenterol}. 2009;104(9):2288-2294.
15. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. \textit{Am J Surg Pathol}. 2001;25:579-586.
16. Hruban RH, Pitman MB, Klimstra DS. \textit{Tumors of the Pancreas. Atlas of Tumor Pathology. 4th Series.} Washington, DC: American Registry of Pathology and Armed Forces Institute of Pathology; 2007.
17. Schwartz AM, Henson DE. Familial and sporadic pancreatic carcinoma, epidemiologic concordance. \textit{Am J Surg Pathol}. 2007;31:645-646.
18. Terhune PG, Phifer DM, Tosteson TD, Longnecker DS. K-ras mutation in focal proliferative lesions of human pancreas. \textit{Cancer Epidemiol Biomarkers Prev}. 1998;7:515-521.
19. Del Chiaro M, Segersvård R, Pozzi Mucelli R, et al. Comparison of preoperative conference-based diagnosis with histology of cystic tumors of the pancreas. \textit{Ann Surg Oncol}. 2014;21:1539-1544.
20. Vege SS, Ziring B, Jain R, et al. American Gastroenterological Association Institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. \textit{Gastroenterology}. 2015;148:819-822.
21. Marchegiani G, Mino-Kenudson M, Sahora K, et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. \textit{Ann Surg}. 2014;261(5):976-983.
22. Sahora K, Castillo C-D, Dong F, et al. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. \textit{Surgery}. 2014;156(3):611-621.
23. Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. \textit{Ann Surg}. 2013;258(3):466-475.
24. Tanaka M. International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas. \textit{Ann Transl Med}. 2015;3(19):286.

How to cite this article: Lazzarin G, Romano L, Coletti G, et al. Branch Duct – IPMN and PanIN, in IgG4-Autoimmune pancreatitis: A case report. \textit{Clin Case Rep}. 2020;8:2111–2115. \text{https://doi.org/10.1002/ccr3.2641}